Eli Lilly and Novo Nordisk have filed their new weight-loss drugs with the FDA, marking a significant step towards making these treatments available to patients. These new drugs differ from existing options like Wegovy and Zepbound, offering potential alternatives for those seeking weight loss solutions. The filing is a positive development for the pharmaceutical industry and patients alike.